NCT06075043尚未招募2 期
A Multicenter, Randomized, Open-label Study of AND017 for the Treatment of Anemia of Cancer in Patients Not Receiving Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 36
- 主要终点
- Percentage of responding patients
研究概览
简要总结
The purpose of this study is to determine the safety and efficacy of various doses of AND017 after 6 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Main Inclusion Criteria:
- •Non-myeloid malignancy diagnosed by cytology/histology.
- •ECOG score 0-2 and expected survival of 6 months or more.
- •The mean value of hemoglobin at screening test and one follow-up test (more than one week between tests) was <10.0 g/dL, with a difference of ≤1.0 g/dL between the two tests.
- •Adequate hepatic and renal function.
- •Total bilirubin < 1.5 x upper limit of normal (ULN).
- •Subjects with Gilbert's syndrome (unconjugated hyperbilirubinemia) have a total bilirubin < 3 x ULN.
- •Aspartate aminotransferase (AST)
- •Alanine aminotransferase (ALT) <2.5 x ULN
- •eGFR >60 mL/min/1.73
排除标准
- •Received chemotherapy, radiotherapy, and other, e.g., immunosuppressive, targeted drug therapy that has a suppressive effect on the bone marrow within 1 month prior to randomization or planned during the trial.
- •A medical history of significant liver disease or active liver disease.
- •A previous history of pure red blood cell remittance
- •A combination of hereditary anemia, iron-granulocytic anemia, acute blood loss, active bleeding (three consecutive positive fecal occult bloods or clinical judgment of the investigator), hemolysis and other conditions that can cause anemia such as iron, folic acid or vitamin B12 deficiency
- •Active infection or inflammatory disease requiring systemic anti-infective therapy within 1 week prior to the first dose, including concurrent autoimmune diseases with inflammatory symptoms (e.g., generalized erythema, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, dry syndrome, celiac disease, etc.)
- •Concurrent retinal neovascularization requiring treatment (diabetic proliferative retinopathy, age-related exudative macular degeneration, retinal vein occlusion, macular edema, etc.).
- •clinically significant bleeding (including the need for blood transfusion or a drop in hemoglobin ≥ 2 g/dL) within 4 weeks prior to the first dose, or a bleeding constitutional or bleeding risk that has not been medically or surgically corrected
- •uncontrolled hypertension (more than one-third of identifiable diastolic blood pressure values > 90 mmHg and/or systolic blood pressure ≥ 160 mmHg at 16 weeks prior to and including screening testing)
- •concurrent congestive heart failure (New York Heart Association [NYHA] class III or higher)
- •clinically significant ECG abnormalities at screening assessment.
- •Have been treated with any hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) in the 8 weeks prior to randomization
- •have received treatment with an erythropoietic agent, androgenic anabolic steroid, testosterone enanthate or methandrostenolone within 6 weeks prior to screening assessment.
- •a history of significant medical or major surgical procedure within 3 months prior to the screening assessment or elective surgery planned during the conduct of the study.
研究组 & 干预措施
AND017 Dose A three times weekly
Experimental
干预措施: AND017 (Drug)
AND017 Dose B three times weekly
Experimental
干预措施: AND017 (Drug)
AND017 Dose C three times weekly
Experimental
干预措施: AND017 (Drug)
结局指标
主要结局
Percentage of responding patients
时间窗: From Baseline to Week 6 or End of Treatment visit
Responding patient is defined as those with a maximum elevated hemoglobin level greater than 10% of baseline from baseline to five weeks after dosing.
次要结局
- Percentage of visits in which subjects maintained a hemoglobin elevation between >10% and 12.0 g/dL above baseline after reaching 10% of baseline(From Baseline to Week 6 or at End of Treatment visit)
- Transfusion treatment rate(From Baseline to Week 6 or End of Treatment visit)
- Maximum change in hemoglobin from baseline to 5 weeks post-dose(From Baseline to Week 6 or End of Treatment visit)
- Percentage of patients who achieve a greater than 10% increase in hemoglobin over baseline during treatment(From Baseline to Week 6 or at End of Treatment visit)
- Percentage of subjects requiring blood transfusions during the trial(From Baseline to Week 6 or at End of Treatment visit)
研究者
相似试验
尚未招募
2 期
A Study of AND017 in Cancer Related Anemic Patients Receiving ChemotherapyChemotherapy Induced AnemiaNCT06075030Kind Pharmaceuticals LLC36
已完成
1 期
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCIAcute Spinal Cord InjuryNCT00406016Novartis52
已完成
2 期
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)Rheumatoid ArthritisNCT00928512Novartis Pharmaceuticals237
已完成
3 期
A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore ThroatSore ThroatNCT03095521Sandoz228
已完成
1 期
A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid TumorsNeoplasmsNCT01143753Hoffmann-La Roche45